Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer

Overview

Journal Antioxidants (Basel)

Date 2019 Dec 5

PMID 31795465

Citations 8

Authors

Cindy Mendes

Jacinta Serpa

Affiliations

Soon will be listed here.

Abstract

Metabolic remodelling is a hallmark of cancer, however little has been unravelled in its role in chemoresistance, which is a major hurdle to cancer control. Lung cancer is a leading cause of death by cancer, mainly due to the diagnosis at an advanced stage and to the development of resistance to therapy. Targeted therapeutic agents combined with comprehensive drugs are commonly used to treat lung cancer. However, resistance mechanisms are difficult to avoid. In this review, we will address some of those therapeutic regimens, resistance mechanisms that are eventually developed by lung cancer cells, metabolic alterations that have already been described in lung cancer and putative new therapeutic strategies, and the integration of conventional drugs and genetic and metabolic-targeted therapies. The oxidative stress is pivotal in this whole network. A better understanding of cancer cell metabolism and molecular adaptations underlying resistance mechanisms will provide clues to design new therapeutic strategies, including the combination of chemotherapeutic and targeted agents, considering metabolic intervenients. As cancer cells undergo a constant metabolic adaptive drift, therapeutic regimens must constantly adapt.

Citing Articles

Phosphodiesterase Inhibition to Sensitize Non-Small-Cell Lung Cancer to Pemetrexed: A Double-Edged Strategy.

Ivanina Foureau A, Foureau D, McHale C, Guo F, Farhangfar C, Mileham K Cancers (Basel). 2024; 16(13).

PMID: 39001537 PMC: 11240499. DOI: 10.3390/cancers16132475.

Unveiling the Nutritional Veil of Sulforaphane: With a Major Focus on Glucose Homeostasis Modulation.

Wang Y, He X, Cheng N, Huang K Nutrients. 2024; 16(12).

PMID: 38931232 PMC: 11206418. DOI: 10.3390/nu16121877.

20-Hydroxyecdysone Confers Antioxidant and Antineoplastic Properties in Human Non-Small Cell Lung Cancer Cells.

Shuvalov O, Kirdeeva Y, Fefilova E, Netsvetay S, Zorin M, Vlasova Y Metabolites. 2023; 13(5).

PMID: 37233697 PMC: 10223942. DOI: 10.3390/metabo13050656.

Landscape and clinical impact of metabolic alterations in non-squamous non-small cell lung cancer.

Ivanina Foureau A, Sha W, Foureau D, Symanowski J, Farhangfar C, Mileham K Transl Lung Cancer Res. 2023; 11(12):2464-2476.

PMID: 36636422 PMC: 9830272. DOI: 10.21037/tlcr-22-377.

Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.

Eltayeb K, La Monica S, Tiseo M, Alfieri R, Fumarola C Cells. 2022; 11(3).

PMID: 35159223 PMC: 8834094. DOI: 10.3390/cells11030413.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Awasthi Y, Singh S, Ahmad H, Moller P . Immunocytochemical evidence for the expression of GST1, GST2, and GST3 gene loci for glutathione S-transferase in human lung. Lung. 1987; 165(6):323-32. DOI: 10.1007/BF02714448. View

Adhikari S, Choudhury S, Mitra P, Dubash J, Sajankila S, Roy R . Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem. 2008; 8(4):351-7. DOI: 10.2174/187152008784220366. View

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Zhang J, Song F, Zhao X, Jiang H, Wu X, Wang B . EGFR modulates monounsaturated fatty acid synthesis through phosphorylation of SCD1 in lung cancer. Mol Cancer. 2017; 16(1):127. PMC: 5518108. DOI: 10.1186/s12943-017-0704-x. View

Shrivastav M, De Haro L, Nickoloff J . Regulation of DNA double-strand break repair pathway choice. Cell Res. 2007; 18(1):134-47. DOI: 10.1038/cr.2007.111. View

Chio I, Tuveson D . ROS in Cancer: The Burning Question. Trends Mol Med. 2017; 23(5):411-429. PMC: 5462452. DOI: 10.1016/j.molmed.2017.03.004. View

Huang Y, Dai Z, Barbacioru C, Sadee W . Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res. 2005; 65(16):7446-54. DOI: 10.1158/0008-5472.CAN-04-4267. View

Liu Y, He C, Huang X . Metformin partially reverses the carboplatin-resistance in NSCLC by inhibiting glucose metabolism. Oncotarget. 2017; 8(43):75206-75216. PMC: 5650413. DOI: 10.18632/oncotarget.20663. View

10.

Zhan M, Liu X . Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. Chin Med J (Engl). 2001; 112(4):336-9. View

11.

Ye M, Zhang X, Li N, Zhang Y, Jing P, Chang N . ALK and ROS1 as targeted therapy paradigms and clinical implications to overcome crizotinib resistance. Oncotarget. 2016; 7(11):12289-304. PMC: 4914285. DOI: 10.18632/oncotarget.6935. View

12.

Murray S, Dahabreh I, Linardou H, Manoloukos M, Bafaloukos D, Kosmidis P . Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database. J Thorac Oncol. 2008; 3(8):832-9. DOI: 10.1097/JTO.0b013e31818071f3. View

13.

Meijerman I, Beijnen J, Schellens J . Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. Cancer Treat Rev. 2008; 34(6):505-20. DOI: 10.1016/j.ctrv.2008.03.002. View

14.

Colla R, Izzotti A, Ciucis C, Fenoglio D, Ravera S, Speciale A . Glutathione-mediated antioxidant response and aerobic metabolism: two crucial factors involved in determining the multi-drug resistance of high-risk neuroblastoma. Oncotarget. 2016; 7(43):70715-70737. PMC: 5342585. DOI: 10.18632/oncotarget.12209. View

15.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

16.

Liu H, Savaraj N, Priebe W, Lampidis T . Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). Biochem Pharmacol. 2002; 64(12):1745-51. DOI: 10.1016/s0006-2952(02)01456-9. View

17.

Tew K . Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 1994; 54(16):4313-20. View

18.

Pavlova N, Thompson C . The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016; 23(1):27-47. PMC: 4715268. DOI: 10.1016/j.cmet.2015.12.006. View

19.

Ilizarov A, Koo H, Kazzaz J, Mantell L, Li Y, Bhapat R . Overexpression of manganese superoxide dismutase protects lung epithelial cells against oxidant injury. Am J Respir Cell Mol Biol. 2001; 24(4):436-41. DOI: 10.1165/ajrcmb.24.4.4240. View

20.

Barabas K, Milner R, Lurie D, Adin C . Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol. 2009; 6(1):1-18. DOI: 10.1111/j.1476-5829.2007.00142.x. View